IDEMIA
16.6.2021 13:32:04 CEST | Business Wire | Press release
The Project Embarque + Seguro 100% Digital Boarding System, using the Brazilian government’s facial recognition, arrives this Tuesday (June 15) at the Congonhas Airport (SP). For the first time in the world, passengers on the air shuttle service between the capitals of São Paulo and Rio de Janeiro will participate in the simultaneous testing of this end-to-end technology without the need to present neither a boarding pass nor an identification document. The Project of the Ministry of Infrastructure, developed in partnership with Serpro and the Special Secretariat of Debureaucratization, Management and Digital Government of the Ministry of Economy, has already been tested at the airports of Florianópolis (SC), Salvador (BA), Santos Dumont (RJ) and Belo Horizonte (Confins).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005505/en/
After the approval of the pilot project, the Federal Government will move forward with actions to effectively implement the technology in major Brazilian airports. The technology aims at making the boarding process at airports more efficient, agile, and secure. "It is the first time that tests are carried out simultaneously in two of our airports, thus establishing, in an unprecedented way, a 100% biometric air shuttle between RJ / SP, which has the fifth-largest movement in the world", highlights the executive secretary of MInfra, Marcelo Sampaio.
Throughout the day, Azul Linhas Aéreas’s passengers travelling between Congonhas and Santos Dumont airports will be invited to try the biometric facial recognition technology to access both boarding area and aircraft at both terminals. "Embarque + Seguro combines biometric validation and data analysis, ensuring an accurate, agile and secure validation of the identity of passengers, who can thus travel with more comfort and tranquility. The solution complies with the General Data Protection Law (LGPD) and is premised on security in the processing of personal data against misuse or unauthorized use", emphasizes the president of Serpro, Gileno Barreto.
For the president of Infraero, Brigadier Paes de Barros, "the air shuttle’s Embarque + Seguro unites two essential items that streamline the boarding processes, which are safety and ease for the passenger and the entire civil aviation system".
According to the Director of Public Security & Identity (PSI) of IDEMIA in Brazil, Márcio Lambert, "Facial recognition is a global trend and the Project Embarque + Seguro, jointly carried out by Minfra and Serpro, shows that Brazil is on the right track to airport digitalization. IDEMIA’s technology is applied in the most modern airports around the world, such as Changi in Singapore, and offers a high level of security for passengers, airlines, and airport operators, as its algorithm is highly accurate, reaching a extremely high authenticity rate in the identification of individuals. IDEMIA is proud to participate in this project along with Brazil’s Federal Government and to enable the world’s first 100% end-to-end digitized boarding system in an executive air shuttle service".
"The latest Global Passengers Research conducted by the International Air Transport Association (IATA) says that 70% of interviewees are willing to share their biometry for identification purposes during the boarding process. Our global expertise contributes to meeting society’s need to fly again. This innovative project developed by the Federal Government allows travelers to enjoy a quieter, safer and more comfortable boarding experience and puts Brazil at the forefront of the digital transformation movement. IDEMIA as a global leader in augmented identity has the mission to facilitate the flow of passengers by creating the possibility to interact and travel in a more connected way. To participate in the first air shuttle with an end-to-end fully digitized boarding system, in both airports, is an important milestone in our history,” explains Rodrigo Costa, PSI business development director at IDEMIA LATAM.
The MFACE technology, developed by IDEMIA, captures facial biometrics in seconds, making the boarding process even more agile, avoiding queues and delays. The solution combines the convenience and security of data validation, respecting the privacy of passengers according to the GDPR, and ensures a more hygienic process by eliminating document and paper handling, thus avoiding the risk of contamination.
"The control of IDEMIA’s biometric system follows high-quality, reliability and safety standards and offers more agility and comfort to passengers, turning the airport operational process more intelligent, the airline passenger identification more accurate, and generates the security required by the government," adds Márcio Lambert.
How it works
When checking in at the airport, the passenger of Azul Linhas Aéreas is invited to participate in the project. If the passenger agrees, then a message is sent to the cell phone informed in the application, requesting authorization to obtain the passenger’s data, including the social security number and a photo. Upon consent, the airline attendant, using the application developed by Serpro for this purpose, performs the biometric validation of the citizen, comparing the data and the photo taken on the spot with the government databases.
After validated, the passenger is released to enter the departure hall and the aircraft passing through biometric control points, whose cameras perform the passenger’s identification without the need for the user to present any document or boarding pass.
Total Security
In the pilot project, indicators such as queue time reduction, access to the departure hall and aircraft are measured, in addition to operating costs. With the tests, it is expected that airport security increases, as facial recognition allows an accurate identification of passengers.
"We are moving towards a fully secure biometric boarding at every airport in the country. In addition to the process being safe from the sanitary point of view, by eliminating the handling of papers during the pandemic, it guarantees the total protection of users' data, because the Embarque + Seguro 100% Digital Boarding System meets all the precepts of the LGPD", says Marcelo Sampaio.
Partnerships
Serpro is MInfra’s strategic partner in the country's transportation digital agenda, but Embarque + Seguro also has the collaboration of airlines and airports where the tests have been carried out, which has enabled the improvement of the project at each stage. The air shuttle pilot test is being implemented with the support of Infraero and Azul Linhas Aéreas; and the technology of facial identification stations was developed by Digicon, IDEMIA and Azul/Pacer companies.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated, and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com
/ Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
